Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00914849 · ClinicalTrials.gov registry record · Phase 2
Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies
A Phase 2 study of Hematologic Neoplasms, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT00914849 is a Phase 2 study of Hematologic Neoplasms that has completed, run by Washington University School of Medicine. The registered enrollment target is 68 participants, below the 1,023-participant average among 20 other Hematologic Neoplasms trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00914849, a Phase 2 study of Hematologic Neoplasms, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
To reduce the number of donors treated with IV AMD3100 who require a second collection to obtain the minimum cells necessary for allogeneic stem cell transplant.
Conditions Studied
Interventions
- DRUG AMD3100
- PROCEDURE Leukopheresis
- PROCEDURE Stem cell transplant
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2009-08 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00914849
The ClinicalTrials.gov registry entry for NCT00914849 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,023-participant average among 20 other Hematologic Neoplasms trials with a reported enrollment target (93% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematologic Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which AMD3100 is the first listed.
NCT00914849 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT00914849 about?
NCT00914849 is a clinical study titled "Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies". To reduce the number of donors treated with IV AMD3100 who require a second collection to obtain the minimum cells necessary for allogeneic stem cell transplant.
What is the current status of trial NCT00914849?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2009-08. Estimated completion is 2012-02.
What conditions does trial NCT00914849 study?
This clinical trial studies the following conditions: Hematologic Neoplasms.
What interventions are being tested in trial NCT00914849?
The interventions under investigation include: AMD3100 (DRUG), Leukopheresis (PROCEDURE), Stem cell transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00914849?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00914849 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil
ACTIVE NOT RECRUITING · Phase 2
-
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
COMPLETED · Phase 2
-
Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant
COMPLETED · Phase 2
-
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
COMPLETED · Phase 2
-
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant
COMPLETED · Phase 2
-
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.